Neoadjuvant chemotherapy and surgery-based treatment with selective adjuvant chemotherapy for cT2N0 esophageal squamous cell carcinoma: a multicenter retrospective study
Esophagus · 2026-10 · 23 (4) · 782-790
DOI: 10.1007/s10388-026-01232-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Esophagus, online erschienen am 28.07.2026. Verfasst von Tomohira Takeoka und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, Japan. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Neoplasms, Esophagectomy, Esophageal Squamous Cell Carcinoma. Die Arbeit nennt 24 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The role of neoadjuvant chemotherapy (NAC) in clinical T2N0 (cT2N0) esophageal squamous cell carcinoma (ESCC) is controversial, largely due to limited evidence and the well-recognized inaccuracy in clinical staging.
Methods
We analyzed 263 patients with cT2N0 thoracic ESCC who underwent subtotal esophagectomy between 2000 and 2019. Patients were grouped into NAC plus surgery (n = 87) and upfront surgery (n = 176); 43 patients in the latter group received adjuvant chemotherapy based on pathological risk factors.
Results
Clinical staging accuracy was low, with only 15.3% of patients clinically diagnosed with T2N0 confirmed as pT2N0. Downstaging to pT1N0 occurred in 23.3% of patients, while 48.3% in the upfront surgery group showed occult pathological nodal metastasis (pN +). Lymphatic (37.2% vs. 64.2%, p < 0.001) and vascular invasion rates were low in the NAC group (20.9% vs. 46.5%, p < 0.001), but residual nodal disease remained common (32.2%). Median follow-up was 59 months. Five-year overall survival (OS) and disease-free survival were comparable between NAC and upfront surgery groups (70.5% vs. 70.6%, p = 0.574; 67.8% vs. 65.8%, p = 0.817, respectively). Recurrence patterns were similar between groups. Among pN + patients in the upfront surgery cohort, adjuvant chemotherapy improved 5-year OS (72.1% vs. 58.7%, p = 0.033), with outcomes similar to pN0 patients.
Conclusion
Routine NAC did not improve long-term survival compared with upfront surgery in cT2N0 ESCC. Upfront surgery followed by selective postoperative adjuvant chemotherapy in patients with pathological nodal involvement was associated with survival outcomes approaching those of pN0 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, Japan.
- Department of Gastroenterological Surgery, Sakai City Medical Center, Osaka, Japan.
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, Japan. hiroshi.miyata@oici.jp.
- Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
- Department of Surgery, NHO Osaka National Hospital, Osaka, Japan.
- Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
Zitieren
APA
Takeoka, T., Miyata, H., Tanaka, K., Nakai, S., Sugase, T., Yamamoto, M., Kanemura, T., Sugimura, K., Makino, T., Takeno, A., Shiraishi, O., Motoori, M., Yamasaki, M., Hirao, M., Fujitani, K., Yasuda, T., Yano, M., & Doki, Y. (2026). Neoadjuvant chemotherapy and surgery-based treatment with selective adjuvant chemotherapy for cT2N0 esophageal squamous cell carcinoma: a multicenter retrospective study. Esophagus, 23(4), 782-790. https://doi.org/10.1007/s10388-026-01232-0
Vancouver
Takeoka T, Miyata H, Tanaka K, Nakai S, Sugase T, Yamamoto M, et al. Neoadjuvant chemotherapy and surgery-based treatment with selective adjuvant chemotherapy for cT2N0 esophageal squamous cell carcinoma: a multicenter retrospective study. Esophagus. 2026;23(4):782-790. doi:10.1007/s10388-026-01232-0
BibTeX
@article{Takeoka2026,
author = {Takeoka, Tomohira and Miyata, Hiroshi and Tanaka, Koji and Nakai, Shigeto and Sugase, Takahito and Yamamoto, Masaaki and Kanemura, Takashi and Sugimura, Keijiro and Makino, Tomoki and Takeno, Atsushi and Shiraishi, Osamu and Motoori, Masaaki and Yamasaki, Makoto and Hirao, Motohiro and Fujitani, Kazumasa and Yasuda, Takushi and Yano, Masahiko and Doki, Yuichiro},
title = {Neoadjuvant chemotherapy and surgery-based treatment with selective adjuvant chemotherapy for cT2N0 esophageal squamous cell carcinoma: a multicenter retrospective study},
journal = {Esophagus},
year = {2026},
volume = {23},
number = {4},
pages = {782--790},
doi = {10.1007/s10388-026-01232-0}
}
EUVIMED